

BENTLEY PHARMACEUTICALS INC  
Form 25  
December 18, 2006

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 25**

**NOTIFICATION OF REMOVAL FROM LISTING AND/OR  
REGISTRATION UNDER SECTION 12(b) OF THE  
SECURITIES EXCHANGE ACT OF 1934.**

Commission File Number: **1-10581**

**Bentley Pharmaceuticals, Inc. and  
NYSE Arca, Inc. (formerly The Pacific Exchange, Inc.)**

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

**Bentley Park, 2 Holland Way, Exeter, New Hampshire 03833 (603) 658-6100**

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

**Common Stock, \$0.02 Par Value,  
Preferred Stock Purchase Rights**

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

Edgar Filing: BENTLEY PHARMACEUTICALS INC - Form 25

- o 17 CFR 240.12d2-2(a)(2)
- o 17 CFR 240.12d2-2(a)(3)
- o 17 CFR 240.12d2-2(a)(4)
- o Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.(1)
- x Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, Bentley Pharmaceuticals, Inc. (Name of Issuer or Exchange) certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

December 18, 2006  
Date

By: /s/ Richard P. Lindsay  
Name

Vice President and CFO  
Title

(1) Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

---